sglt2 inhibitors and glp 1 receptor agonists Diabetic Agents, From Metformin to GLP1 Agonists: JACC Focus Seminar SGLT-2 Inhibitors and GLP-1 Agonists:
Description
(2021) of the CVOTs found that the GLP-1 RAs are associated with a significant 14% relative risk reduction in terms of major adverse cardiovascular events (MACE, a standard 3-component composite endpoint) (hazard ratio [HR] 0.86
The review was conducted in accordance with established methodological guidance for narrative reviews (38)
Garg SK, et al
Most patients choose fillers because they offer visible improvement without surgery
